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Abstract 
Many biological markers are associated with poor prognosis in chronic lymphocytic 
leukemia (CLL), but their mechanistic role remains unclear. Bax is an essential pro-
apoptotic protein and decreased levels in malignant cells lead to resistance to apoptosis.  
Using a Bax degradation activity (BDA) assay, CLL cells were found to show variable 
Bax instability. However, BDA did not correlate with Bax protein levels: BDA positive 
and negative cases had high and low baseline Bax levels. BDA positive cases showed a 
marked accumulation of poor prognostic markers – unmutated immunoglobulin heavy 
chain variable genes, ZAP-70/CD38 positivity, 11q22/17p13 deletion, and short 
lymphocyte doubling time.  Patients with BDA positive cells had a shorter median overall 
survival (OS) (126 months v. not reached, p = 0.011) and time to first treatment (16 v. 
156 months, p = 0.029) than BDA negative cases. Dual BDA and ZAP-70 positivity had 
a median OS of 84 months (p = 0.012). The BDA assay measures the intrinsic 
ubiquitin/proteasome activity of CLL cells and dynamic changes in Bax protein levels 
over time. Mechanistically, Bax instability may represent a final common pathway for 
disparate prognostic markers, as well as being itself an indicator of poor prognosis.  
Key words: CLL; Bax; ZAP-70; CD38; Ig VH; cytogenetics. 
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Introduction 
The clinical course of B-cell chronic lymphocytic leukemia (CLL) is highly 
heterogeneous.  Disease progression and survival correlate not only with clinical 
parameters, but also with a plethora of biological prognostic markers, including 
immunoglobulin (Ig) heavy chain variable gene (VH) mutation status,1,2  ZAP-70,3-5 
CD38 expression.1 Recurrent cytogenetic abnormalities, with loss of the short arm of 
chromosome 17 (17p deletion), confer a very poor prognosis6 with the presumed 
mechanism of action involving (at least) loss of p53.  Furthermore, functional loss of p53 
activity, even in cases without a detectable p53 mutation, has been suggested as one 
mechanism underlying the poor prognosis associated with unmutated Ig VH genes.7 The 
molecular mechanisms underlying the worse prognosis in CLL with unmutated Ig VH, 
ZAP-70 or CD38 expression also remain elusive, although enhanced cell 
signaling/survival have been implicated.8-10  The role of ZAP-70 in enhancing signaling 
has been questioned in recent work showing that B-cell receptor triggering was not 
influenced by the ZAP-70 status of CLL cells.11 Clearly, further work is required to 
elucidate the cellular and molecular mechanisms that underlie the observed clinical value 
of these prognostic markers. 
Fundamental to all malignant cells is the property of uncontrolled cell growth, 
often combined with resistance to apoptosis – a characteristic feature of CLL cells. A key 
pro-apoptotic protein is Bax, with low levels of, or absent, Bax expression in malignant 
cells being associated with resistance to treatment.  Several pro-apoptotic molecules have 
been shown to be regulated by the ubiquitin/proteasome pathway, including p53,12 Bid,13  
Bax,14,15 ARTS16 and NOXA.17 Furthermore, Bax instability was found in malignant cells 
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and cell lines,15,18 as well as primary CLL cells.19  In the accompanying paper (Liu et al,), 
we investigated Bax degradation activity in cell lines, its role in TNF-related 
apoptosis inducing ligand (TRAIL)-induced apoptosis of CLL cells and its 
modulation by proteasome inhibition.  Bax degradation in cell lines was found to be 
located in mitochondria, as opposed to the cytosol, and required an active 
ubiquitin/proteasome machinery. Bax instability was a mechanism of resistance to 
TRAIL-induced apoptosis, with proteasome inhibitors overcoming this resistance by 
stabilizing Bax and preventing degradation of ubiquitinated Bax.  These findings 
suggested that testing for Bax instability in CLL may help guide therapeutic choices, with 
marked Bax degradation activity indicating that combined TRAIL and proteasome 
inhibition could be useful in some patients. This paper further investigates the utility of 
measuring Bax instability in CLL.  We looked at a cohort of patients with CLL and 
compared Bax degradation activity with established prognostic markers: Ig VH mutation 
status, ZAP-70, CD38, cytogenetics, as well as clinical stage and lymphocyte doubling 
time (LDT). 
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Materials and Methods 
Cell culture and clinical samples 
The protocol was approved by our local Ethical Committee.  The diagnosis of CLL was 
made by standard criteria: cellular morphology and immunophenotyping (CD5+, CD19+, 
CD23+, weak surface Ig staining and weak CD79b with FMC7 negativity).  All cases had 
a significant lymphocytosis of > 40 x 109/L.  Peripheral blood was obtained after written 
informed consent from patients with CLL.  Patients had either never received treatment 
for their CLL or were at least 6 months post their previous course of treatment.  
Mononuclear cells were isolated by density centrifugation over Ficoll. Cells were 
cultured in RPMI-1640 medium (Sigma) supplemented with 10% heat-inactivated fetal 
calf serum (FCS), 25 mM HEPES, 2.0 mM L-glutamine, pH 7.4, at 37°C in a 5% CO2 
humidified incubator.  
Prognostic markers in CLL: ZAP-70 and CD38 by flow cytometry  
ZAP-70 and CD38 by flow cytometry are routinely available as part of the diagnostic 
work-up for all CLL cases in our immunophenotyping laboratory.  Briefly, direct staining 
of whole blood with conjugated anti-CD38-PE, clone T16, (Beckman Coulter, Villepinte, 
France) and anti-CD19-FITC, clone J4.119 (Beckman Coulter) was performed, followed 
by red cell lysis using the Beckman-Coulter ImmunoPreP reagent system and samples 
were read on a Coulter XL4-MCL flow cytometer.  CD38 positivity was set at a threshold 
of > 20%.  Intracellular staining for ZAP-70 involved: initial surface marking with anti-
CD3-PE (UCHT1) (Beckman Coulter) and CD56-PE (N901[NKH-1]) (Beckman 
Coulter), permeabilization with Dako Intrastain (Dako, Cambridgeshire, U.K.) and 
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labeling with anti-ZAP-70, clone 2F3.2, (Upstate-Millipore) followed by a goat-anti-
mouse pan IgG (H+L) FITC (Southern Biotechnology, Alabama, U.S.A.).  CLL ZAP-70 
expression was assessed by gating out CD3 and CD56 positive cells.  Positivity was set at 
a threshold of > 20%.  
 Prognostic markers in CLL: Analysis of somatic mutation of the rearranged 
immunoglobulin heavy chain (IgVH) genes   
DNA was extracted from peripheral blood leukemia cells – in some cases from fixed, 
stained slides - using QIAamp DNA Blood Mini kit (Qiagen, Crawley, West Sussex, 
U.K.) and subjected to PCR of the rearranged immunoglobulin heavy chain gene from 
the framework 1 to the joining region using the BIOMED-2 multiplex PCR protocols 
(InVivoScribe Technologies, LLC, San Diego, CA, USA).  PCR products were analyzed 
by polyacrylamide gel electrophoresis and clonal PCR products were purified using 
QIAquick PCR purification kits (QIAGEN), followed by direct sequencing twice with the 
consensus primer to the joining region on an ABI 377 DNA sequencer.  In cases where 
direct sequencing failed, PCR products were cloned and at least four clones were 
sequenced using vector primers. The consensus sequence in each case was subjected to 
database search for identification of the variable (V), diversity (D) and joining (J) 
germline segments used and somatic mutation in the rearranged V segment using 
DNAPLOT and VBASE2 (http://www.vbase2.org/).   
Prognostic markers in CLL: cytogenetic analyses 
Interphase FISH analysis was performed using the commercially available Vysis CLL 
probes (Abbott Diagnostics) to detect the common CLL associated abnormalities; 
deletions of ATM (11q23), D13S319 (13q14) and p53 (17p13), trisomy 12 using a 
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chromosome 12 centromere probe (CEP12). FISH was also set up to exclude the presence 
of the t(11;14) , ICH/CCND1 associated with mantle cell lymphoma. The probes were 
applied as dual colour probe pair sets (ATM/p53, D13S319/CEP12 and IGH/CCND1) 
and used according to the manufacturers protocol. For each probe set, 100 interphases 
were scored on Leica DMXRA microscope fitted with a COHU CCD camera using 
MacProbe V4.1.1 CGH software (PSI/Applied Imaging).  
In vitro Bax degradation assay 
CLL cells were incubated in the Buffer A (250 mM sucrose, 10 mM HEPES-KOH, pH 
7.4, 10 mM KCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 0.1 mM PMSF, protease 
inhibitor cocktail 1:100, 50 µg/ml creatine phosphokinase, 10 mM phosphocreatine, 2 
mM ATP, and 0.1% Triton X-100) for 20 minutes on ice.  Cells were then broken with a 
glass Dounce homogenizer (Jencons, Leighton Buzzard, U.K.) and nuclei removed by 
spinning at 790 ×g for 10 minutes at 4°C.  The post-nuclear supernatant was used as the 
cellular extract for the Bax degradation activity (BDA) assay.  After the addition of 2 
µg/ml ubiquitin (Sigma, Dorset, U.K.), the protein extract in 5 mg/ml concentration was 
incubated at 37°C for up to 5 hours in the Buffer A in the presence of the ATP 
regeneration system and protease inhibitor cocktail.  Proteins were taken out hourly and 
Bax levels determined using Western blotting and subsequent measurement of band 
density. BDA was calculated as the ratio of Bax level at three hours in the assay, 
compared with its level at time 0.   Samples with less than 20% Bax degradation (BDA 
>0.8) were considered BDA negative.  
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 Western blotting 
In order to assess Bax expression, CLL cells were placed in lysis buffer (1% Triton X-
100, 0.5% sodium deoxycholate, 0.1 SDS, 1 mM PMFS, 10 μg/ml aprotinin, 10 μg/ml 
leupeptin, 1 mM sodium orthovanadate, 1 mM DTT in PBS, pH 7.4). Proteins were 
subjected to standard SDS-PAGE at 20-40mA/gel and transferred on to PVDF membrane 
at 100 V for 1 hour.  PVDF membrane was blocked with 1% non-fat milk in PBST for 1 
hour and probed for various proteins using the monoclonal anti-Bax 2D2 antibody, clone 
YTH-2D2 (R & D Systems, Oxon, U.K.) or the monoclonal anti- anti-β-actin antibody 
(Sigma).  Bound antibodies were detected using HRP-conjugated anti-mouse antibody 
(Santa Cruz, U.S.A) followed by detection using SuperSignal West Pico 
Chemiluminescent Substrate (Perbio Science UK Ltd. Northumberland, U.K.). The 
density of each band was analyzed using an AlphaImagerTM  2000 Densitometer (Alpha 
Innotech Corp. San Jose, CA).  
Statistical analysis  
Binary comparisons between Bax degradation activity (positive or negative) were made 
with Binet stage (A or not A), presence of IgVH mutation, ZAP-70 and CD38 positivity, 
LDT (>12 months or other), karyotype (11q- or 17p- / other) using Chi-square with 
Yate’s correction or 2-sided Fisher’s Exact test, as appropriate.  Survival time and time to 
treatment between Bax groups was compared using Kaplan-Meier plots and Cox’s F test.  
Multivariate analysis was undertaken using a generalized non-linear binomial model 
using logit analysis. Statistical significance was assumed at a p-value of < 0.05. 
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Results 
Bax instability in CLL cells 
In the accompanying paper, Bax protein levels were found to vary with individual 
malignant B-cell lines. This variation was not related to Bax mRNA expression, 
suggesting regulation at the post-translational level (Liu et al,).  A specific defect of Bax 
stability was found in malignant B-cells and BDA was higher in these than in control 
tissues.  In this paper, the work has been extended to 40 cases of CLL.  In these patients, 
Bax degradation was positive (active) in 26 out of 40 cases, but negative in normal 
peripheral blood lymphocytes (Figure 1).  The level of Bax instability varied and is 
shown schematically as ‘+’ to ‘+++’ in Figure 1.  No degradation in Bak, Bcl-2, Bcl-XL 
was detected in CLL cells. NOXA and PUMA proteins were not expressed in 
unstimulated CLL cells (results not shown).  
Bax degradation activity does not correlate with Bax protein levels 
It was important to establish whether the differential responses in the BDA assay were 
related to the baseline level of Bax protein in CLL cells. Bax protein expression was 
tested in 15 CLL samples – 8 BDA positive and 7 BDA negative. Figure 2 shows that 
there was no correlation between BDA and Bax protein levels, with BDA positive and 
negative cases having both high and low levels of basal Bax.  
Bax degradation activity is associated with poor prognostic markers in CLL  
The instability of Bax protein in CLL cells, as indicated by the BDA assay, could 
represent a new prognostic marker with biological relevance. Therefore, we looked at the 
correlation of BDA with established prognostic markers. The characteristics of the cohort 
 9
of 40 cases of CLL are shown in Table 1.  Overall, 27% (11/40) of cases were Binet stage 
B/C at diagnosis, while 48% (19/40) had a LDT <12 months (including cases requiring 
therapy before the LDT could be established).  In terms of biological parameters, 45% 
(13/29) of cases had unmutated Ig VH, 38% (15/39) were ZAP-70 positive, 45% (18/40) 
CD38 positive and 15% (6/40) had 11q22 or 17p13 deletions. In our diagnostic practice, 
with a population of nearly 2 million, ZAP-70 and CD38 positivity are typically seen in 
one third of cases (data not shown).  Thus, this cohort of patients with CLL appears to 
represent a higher risk population than the general CLL population, which is in keeping 
with the bias of a tertiary referral center, as recognized in the literature.3,5   
The identification of two populations of CLL cases – those in whom the cells had 
stable Bax and those that showed Bax instability – led us to investigate the distribution of 
various prognostic markers in the two groups.  The 26 cases showing Bax degradation 
activity (BDA positive) had a marked accumulation of poor prognostic features (Table 2): 
10/11 of the Binet stage B/C patients, 9/13 Ig VH unmutated cases, 12/15 of the ZAP-
70+, 15/18 of the CD38+, 15/19 of the LDT <12 months patients, and all of the six 11q22 
or 17p13 deletion cases.  However, probably because of a lack of power, individually, 
none of these apparent associations with BDA positivity were statistically significant 
(Table 2),  
Bax degradation activity is associated with poor outcomes in CLL  
Median OS in the BDA positive group was 126 months, which was significantly worse 
than in the BDA negative group (p = 0.011) (Figure 3); and the median time to treatment 
was 16 months compared to 156 months for the BDA negative group (Figure 4) (p = 
0.029). The median OS and time to treatment for VH mutation, ZAP-70 and CD38 are 
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also shown in Figures 3 and 4, respectively. The only combination of parameters which 
improved prognostication were: BDA+ / ZAP-70+ (84 months, p = 0.012); BDA+ / Binet 
stage B/C and CD38+ (31 months, p = 0.001) (Figure 4). Similarly, with respect to time 
to first treatment, BDA positivity was as useful as the other biological parameters, 
(Figure 3) and no combination of BDA+ with unmutated VH, ZAP-70+ or CD38+ 
improved the prognostic value. As Binet stage B/C and LDT < 12 months are themselves 
criteria for instituting therapy for CLL, these parameters confound the interpretation of 
time to treatment analyses. Multivariate analysis with BDA, VH status, ZAP-70, CD38 
and caryotype, looking at survival, only identified unmutated VH as being significant (p 
= 0.005). With respect to time to first treatment, no parameter was found to be significant 
in multivariate analysis. 
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Discussion 
B-CLL is characterized by long-lived cells in vivo, high levels of anti-apoptotic Bcl-2 and 
remains an incurable disease requiring repeated treatments. Pro- and anti-apoptotic 
members of the Bcl-2 family of proteins play a key role in the balance between cell death 
and survival. Low levels, or absence, of the pro-apoptotic molecule, Bax, have been 
associated with resistance to apoptosis in a variety of malignant B-cells.18-20 Bax 
degradation activity, or loss of Bax protein expression, is associated with poor prognosis 
in prostate cancer and melanoma.15,21 In CLL, low Bax levels (mRNA and/or protein 
expression) have been associated with a poor prognosis,22-25 but this has not been 
confirmed in other studies.26,27 The present study has looked at Bax protein instability – 
measured using the BDA assay.  Bax instability was more common in poor prognosis 
CLL and patients with BDA positive cells had a worse prognosis, with a shorter interval 
from diagnosis to first treatment and a shorter overall survival. 
The BDA assay measures the dynamic changes in Bax protein level in CLL cells 
over time. Interestingly, there was no correlation between BDA and basal cellular Bax 
protein levels. This highlights the duality of protein regulation - namely, synthesis and 
degradation. The measurement of a Bax protein level at a single point in time must reflect 
the balance of these two processes – however, a high level of Bax could still be 
associated with high degradation activity if counterbalanced by increased synthesis. As 
the BDA assay uses post-nuclear extracts, the synthetic arm of Bax regulation has been 
eliminated and the assay provides an in vitro measure of the ubiquitin/proteasome 
degradation activity. Thus BDA is a dynamic indicator of intrinsic ubiquitin/proteasome 
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activity in CLL cells and is a one-way ‘output’ (i.e., degradation) assay - without the 
synthetic ‘input’ arm. BDA could therefore be a more robust tool for prognostication and 
may partly explain why the literature contains contradictory reports on the prognostic 
value of Bax protein measurements in CLL.22-27  
The BDA positive cases showed a marked accumulation of known poor 
prognostic features, shorter overall survival and time to first treatment as compared to the 
BDA negative group (Table 2 and Figures 3 and 4).  Analysis of the cases with 
prognostically discordant results further supports the value of the BDA assay.  For 
example, Bax instability (BDA positivity) conferred a poor prognosis in patients without 
other poor risk markers; stability of the Bax protein (BDA negativity) may have 
contributed to the longer than expected survival of patients who had other poor 
prognostic markers, suggesting persistent sensitivity of their cells in vivo to therapeutic 
agents. 
 CLL remains an incurable disease requiring repeated courses of treatment, with a 
decreasing success of therapies due to progressive bone marrow failure, immune 
suppression, infection and resistance to therapy. There is a need for therapies with novel 
mechanisms of action and reduced toxicities. We have shown that Bax instability plays a 
key role in the resistance of CLL cells and malignant B-cell lines to TRAIL-induced 
apoptosis (Liu et al, accompanying paper). Furthermore, we showed that it was possible 
to stabilize Bax with the proteasome inhibitor, Bortezomib, thereby sensitizing CLL cells 
to killing by TRAIL.  
Bortezomib has shown anti-tumor activity in vivo in a number of cancer types, 
especially B-cell malignancies.28 In myeloma, both as a single agent and in combination 
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with other treatments, Bortezomib has an established role in the therapeutic 
armamentarium.29,30 However, the efficacy of Bortezomib in patients with CLL has been 
disappointing.31 The in vitro sensitization of CLL cells to apoptosis by Bortezomib 
suggests that combination of proteasome inhibition with other therapies should be 
investigated in vivo. Recent studies suggest that synergy with Bortezomib and TRAIL 
(Liu et al, accompanying manuscript and 32), chemotherapeutic agents33, or Bortezomib 
and monoclonal anti-CD20 and anti-CD52 antibodies,34 may allow dose reduction of the 
individual agents, thereby minimizing their overall toxicities. 
The BDA assay described here measures the intrinsic Bax instability of CLL cells 
and represents a new prognostic marker, with BDA positivity correlating with shorter 
survival and earlier treatment.  There was a striking accumulation of established markers 
of poor prognosis in cases with Bax instability, suggesting that Bax instability may be a 
common ‘final’ pathway found in poor prognosis CLL and possibly other B-cell 
malignancies (this paper and Liu et al,).   These findings will be extended to a larger, 
prospective study of the utility of the ubiquitin-mediated Bax degradation assay at 
diagnosis in uniformly treated patients, as well as with novel combinations, in CLL. 
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Figure legends 
Figure 1. Bax degradation activity in primary CLL cells.  
The post-nuclear supernatants were extracted from PBL from a healthy donor and CLL 
cells and incubated with the ubiquitin and ATP regeneration system for up to 5 hours. 20 
μg proteins were loaded in each lane for SDS-PAGE. The Bax (clone 2D2) antibody was 
used in 1:1000 dilution and the β-actin antibody was used at 1:10,000 dilution. Numbers 
under each pairs of blots are ratios of Bax/β-actin. Top panel shows results for a normal 
donor; lower 4 panels are cases of CLL.  
Figure 2. Bax protein levels in different CLL patients. 
Proteins were extracted from 15 different CLL samples using the lysis buffer. 20 μg 
proteins were loaded each lane for SDS-PAGE. The Bax (clone 2D2) antibody was used 
in 1:1000 dilution and the β-actin antibody was used at 1:10,000 dilution. BDA positive 
(+) and negative (-) cases are indicated above each lane.  
Figure 3.  Survival according to Bax degradation activity, VH, ZAP-70 and CD38 
status: Bax instability confers a worse prognosis. 
Kaplan-Meier plots of survival since diagnosis in patients classified according to a) BDA, 
b) VHmut, c) ZAP-70, and d) CD38 status, and also in patients with the combined 
markers e) BDA + and ZAP-70 +, and f) BDA +, Binet stage B or C, and CD38 +, 
compared with the remainder.  Cox F test is used to compare the two groups in each plot.  
n = number of patients, O indicates patient is dead, + indicates patient is alive at time of 
analysis. 
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Figure 4.  Time to first treatment according to Bax degradation activity, VH, ZAP-
70 and CD38 status: Bax instability is associated with the need for early treatment. 
Kaplan-Meier plots of time to first treatment since diagnosis in patients classified 
according to a) BDA, b) VHmut, c) ZAP-70, and d) CD38 status.  Cox F test is used to 
compare the two groups in each plot.  n = number of patients, O indicates time of first 
treatment, + indicates patient is untreated at time of analysis. 
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Table 1: Association between Bax degradation activity, prognostic markers and clinical outcome 
Case 
No. 
Bax 
degradation 
activity 
Binet 
stage 
IgVH
mutation 
(%) 
ZAP-70 CD38 LDT (months) Caryotype
1
Treatment -  
months from 
diagnosis 
Survival - 
months from 
diagnosis 
CLL-1 Pos A 0 + + 10 (D13S319x1) Y 12 alive 63 
CLL-2 Pos B 0 + + N/A (ATMx1), (D13S319x1) Y 2 alive 81 
CLL-3 Pos C 0 + + N/A na Y 1 dead 30 
CLL-4 Pos A 3.6 - - >12 (D13S319x1) Y 36 alive 39 
CLL-5 Pos A na - - >12 (D13S319x1) N  alive 135 
CLL-6 Pos A 0 + - N/A (D13S319x1), (p53x1) Y 2 dead 126 
CLL-7 Pos A 1 + - 6 (D13S319x1) N  dead 36 
CLL-8 Pos C 1.7 - - N/A +12, +19 Y 1 dead 210 
CLL-9 Pos B 3.6 + + 6 Normal Y 10 alive 33 
CLL-10 Pos A 7.6 + + 4 (D13S319x1)/ (D13S319x0) (CEP12x3) N 
 alive 63 
CLL-11 Pos A na + - >12 del(11)(q22q23) Y 39 alive 69 
CLL-12 Pos B 2.9 + + 7 Complex# Y 1 dead 18 
CLL-13 Pos A 12.5 - + >12 (D13S319x1)/ (D13S319x0) Y 108 alive 123 
CLL-14 Pos A 0 + + >12 (ATMx1) Y 54 dead 84 
CLL-15 Pos A 0.7 + + >12 (D13S319x1)/ (D13S319x0) N  alive 60 
CLL-16 Pos B na - + N/A Complex* Y 0.25 dead 10 
CLL-17 Pos A 8.7 - + >12 (D13S319x1)/ (D13S319x0) (CEP12x3) Y 
72 alive 111 
CLL-18 Pos B 0 + + 6 Normal Y 12 dead 144 
CLL-19 Pos A na - - >12 (D13S319x1)/ (D13S319x0) (p53x1) N 
 alive 41 
CLL-20 Pos C na - + >12 Normal Y 9 dead 31 
CLL-21 Pos A na - - >12 Normal N  alive 12 
CLL-22 Pos A 5.7 - + N/A (D13S319x1) Y 4 alive 75 
CLL-23 Pos B 4.0 - - 7 (D13S319x0) Y 12 alive 15 
CLL-34 Pos B 6.0 - - N/A (D13S319x1)/ (D13S319x0) (CEP12x3)/ (IGHsp) Y 1 
alive 11 
CLL-37 Pos A 9.4 - - >12 (D13S319x1) Y 36 alive 43 
CLL-38 Pos A 8.0 - + 6 (D13S319x1)/ (D13S319x0) N  alive 27 
CLL-24 Neg A 10 - - >12 (D13S319x1)/ (D13S319x0) N  alive 75 
CLL-25 Neg A 0 + + N/A (CEP12x3) Y 4 dead 144 
CLL-26 Neg A 15.9 - - >12 Normal Y 180 alive 195 
CLL-27 Neg A 8.8 - - >12 (D13S319x1) N  alive 63 
CLL-28 Neg A na - - >12 (D13S319x0) N  alive 135 
CLL-29 Neg A 7.4 - - >12 (D13S319x1)/ (D13S319x0) Y 156 alive 171 
CLL-30 Neg A na na + >12 t(6;13)(p21;q14),add(14)(q32)/ (D13S319x1) Y 
90 alive 123 
CLL-31 Neg A na - - >12 (D13S319x1)/ (D13S319x0) N  alive 123 
CLL-32 Neg A na - - 3 (D13S319x1)/ (D13S319x0) Y 2 alive 147 
CLL-33 Neg A 1.2 - - >12 (D13S319x1)/ (D13S319x0) N  alive 123 
CLL-35 Neg B 0 + + 10 Normal N  alive 15 
CLL-36 Neg A 1.0 + - > 12 +12,del(14)(q13q32)/ (CEP12x3) Y 25 
alive 66 
CLL-39 Neg A na - - >12 Normal N  alive 70 
CLL-40 Neg A 5.0 - - 9 (D13S319x1) Y 34 alive 45 
 
Binet clinical stage at diagnosis; IgVH : using < 2% as the threshold for unmut: unmutated; mut: mutated; LDT: lymphocyte doubling time; na: not available; N/A: not 
applicable (treatment started before LDT assessable); N: no; Y: yes; Pos: positive; Neg: negative. 
1: D13S319 = probe for 13q14, ATM = probe for 11q22, CEP12 = chromosome 12 enumeration probe, IGH\= probe for 14q32, p53 = probe for 17p13; x1 = monoallelic 
deletion, x0 = biallelic deletion; Normal = all FISH probes were present in two copies; Complex = more than 3 cytogenetic abnormalities; 
#: complex includes loss of 9p, partial trisomy 12q, loss of 17p. 
*: complex includes del (13) (q1q2) and 14q32 rearrangement. 
Table 2: Association between Bax degradation activity, established prognostic markers and clinical outcome 
 
 
 
Bax degradation 
activity 
Binet stage 
A /  B or C 
IgVH
mut / unmut 
ZAP-70 
- / + 
CD38 
- / + 
LDT 
>12  / <12 
Caryotype 
 other / 11q-, 17p- 
Treatment  
no / yes 
Survival 
alive / dead 
 
Positive (n = 26) 
 
16 / 10 
 
11 / 9 
 
14 / 12 
 
11 / 15 
 
11 / 15 
 
20 / 6 
 
7 / 19 
 
17 / 9 
 
Negative (n =14) 
 
13 / 1 
 
5 / 4 
 
10 / 3 
 
 11 / 3 
 
10 / 4 
   
14 / 0 
 
7 / 7 
 
13 / 1 
P value 0.06* 0.65* 0.29 0.06 0.15 0.07* 0.18* 0.07* 
 
LDT: lymphocyte doubling time (<12 includes cases where treatment was started before LDT could be assessed); Binet clinical stage at diagnosis; IgVH : using < 2% as the 
threshold for unmut: unmutated; mut: mutated; 11q-: 11q22 deletion by FISH or G-banding; 17p-: 17p13 deletion by FISH or G-banding. 
*: Tests were 2-sided Fisher’s exact test; otherwise p values were obtained using Chi-square with Yate’s correction. 
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Figure 2. Bax expression in CLL
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Figure 3. Survival according to Bax degradation activity,  VH, ZAP70 and CD38 status: 
Bax instability confers a worse prognosis
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Figure 4. Time to first treatment according to Bax degradation activity, VH, ZAP70 and CD38 status: 
early treatment is associated  with Bax instability
